New hope for rare cancers: targeted pill shrinks tumors in early trial
NCT ID NCT04879121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called larotrectinib in people aged 16 and older whose advanced solid tumors have too many copies of the NTRK gene. The drug blocks enzymes that help cancer cells grow. Researchers will measure how many patients' tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Vaccine trains immune system to hunt down cancer cells
- Gut radiation may revive immunotherapy in resistant cancers
- One shot: could a single radiation dose control metastatic cancer?
- Can talking about stress ease Cancer's mental toll? new study aims to find out
- Mayo clinic hunts for hidden cancer clues in DNA and proteins